TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34258913
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (evolocumab, 140 mg, once every 2 weeks on top of atorvastatin 20 mg per day)
Study: 34258913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Atorvastatin only)
Study: 34284351
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg/kg (placebo)
Study: 34049837
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention (exercise + education) including bi-weekly supervised exercise sessions and 30 min of education for 16 weeks (8 weeks supervised + 8 weeks self-guided with phone coaching)
Study: 34604969
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) with 4.8 mL of SonoVue
Study: 34232137
Drug: Randomized controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled trial of CDI treatment in children
Study: 35970020
Drug: Corbevax (two‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corbevax (two‐dose schedule with 28 days of interval between doses)
Study: 35970020
Drug: Corbevax with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corbevax with 750 µg of CpG1018
Study: 33455117
Drug: Osteosarcoma cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteosarcoma cell lines MG63 and HOS with methylation inhibitor
Study: 35485658
Drug: Therapeutic exercises
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercises with an instructor, low‐intensity laser therapy, and PLFEF
Study: 32363972
Drug: Pre-infusion single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-infusion single-dose mesenchymal stem cells (1 × 10^6 cells/kg)
Study: 35728875
Drug: Spartalizumab 400
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally two times daily and trametinib 2 mg orally one time daily
Study: 32675595
Drug: Heated intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated intraperitoneal chemotherapy (HIPEC)
Study: 34441967
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (triamcinolone 0.05%)
Study: 33331846
Drug: Taxane chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane chemotherapy with indoximod
Study: 33331846
Drug: Taxane chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane chemotherapy without indoximod (control)
Study: 34181478
Drug: 372 mg
Normalized name: zinc oxide 0.00372 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 372 mg ISAVUSULF intravenous solution via nasogastric tube
Study: 34181478
Drug: 372 mg
Normalized name: zinc oxide 0.00372 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 372 mg ISAVUSULF capsules for oral administration
Study: 35711602
Drug: Intranasal Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Normal Saline (NS)
Study: 34463032
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid (240 mg/day, supratherapeutic dose)
Study: 32398091
Drug: Cruciferous vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciferous vegetables (4 servings, 300 g per day as a soup, 500-600 mL/day)
Study: 33568343
Drug: Low-dose fractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fractionated radiation (LDFRT) with PD-L1/CTLA-4 inhibition
Study: 32623230
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income supplement
Study: 32623230
Drug: Bimonthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly income supplement
Study: 32841158
Drug: Sexuality education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexuality education program (four weekly 2-hour sessions)
Study: 33524970
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg once daily
Study: 35077638
Drug: Muscle Energy
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Energy (ME) treatment
Study: 35077638
Drug: High-Velocity Low-Amplitude
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Velocity Low-Amplitude (HVLA) treatment
Study: 35077638
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of post-first-treatment values to pre-second-treatment values
Study: 36062735
Drug: Moving to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moving to Opportunity treatment (housing vouchers)
Study: 32283078
Drug: Pedicled buccal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicled buccal fat pad (group A)
Study: 35979900
Drug: Generic fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic fidaxomicin (test formulation)
Study: 35979900
Drug: Original brand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original brand fidaxomicin (reference formulation)
Study: 36398900
Drug: Morning intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning intake of antihypertensive medications
Study: 36398900
Drug: Evening intake
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening intake of antihypertensive medications
Study: 33947979
Drug: Topical loteprednol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical loteprednol etabonate (0.1%) and topical olopatadine (0.1%)
Study: 33748058
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of biomarkers from stratum corneum (SC) samples for internal UV-dose.
Study: 33748058
Drug: Personal UV-sensors
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal UV-sensors worn by workers to assess external UV-dose.
Study: 32503662
Drug: Hydroxychloroquine sulphate
Normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulphate (400 mg twice daily for seven days)
Study: 33781107
Drug: Ketamine (0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.44 mg/kg)
Study: 33208099
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (30 mg/kg loading dose over 10 min, then 10 mg/kg per h until 10 min before end of surgery)
Study: 33345840
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (fasting <90 mg/dL, 1 hour postprandial <120 mg/dL)
Study: 33345840
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic control (fasting <95 mg/dL, 1 hour postprandial <140 mg/dL)
Study: 35710213
Drug: Pilates program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates program twice a week for 10 weeks
Study: 33474815
Drug: Oral synbiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral synbiotics supplement (1 sachet daily for 12 weeks)
Study: 33474815
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 sachet daily for 12 weeks)
Study: 35973827
Drug: MitoHeal® 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoHeal® 500 mg/day
Study: 35973827
Drug: MitoHeal® 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoHeal® 1000 mg/day
Study: 34913186
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg every 4 weeks
Study: 34267550
Drug: galcanezumab 300
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: galcanezumab 300 mg
Study: 33967202
Drug: Gemcitabine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine maintenance therapy after gemcitabine + platinum combination therapy
Study: 33967202
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + platinum combination therapy
Study: 34100024
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of SARS-CoV-2 antibodies
Study: 35449818
Drug: Copaiba oil
Normalized name: COPAIBA OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaiba oil (CPO) inhalation
Study: 36465342
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose
Study: 32160422
Drug: Olanzapine +
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine + 10 mg samidorphan tablets (OLZ/SAM)
Study: 32160422
Drug: Olanzapine +
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine + placebo tablets (olanzapine)
Study: 35546060
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention for nursing staff on appropriate medication therapy and guidance to recognize potentially harmful medications and adverse effects
Study: 32956576
Drug: Delayed calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed calcineurin inhibitor (CNI) substitution
Study: 32067132
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=7), received care as usual (occupational therapy, music therapy, and exercise).
Study: 38781013
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or standard treatment)
Study: 32608989
Drug: Integrated Approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Approach of Yoga Therapy (IAYT), 3 classes per week for 12 weeks
Study: 32281466
Drug: Multisensory perceptual
Normalized name: TITANIUM DIOXIDE 17.6 mg in 1 mL / ZINC OXIDE 41.2 mg in 1 mL TOPICAL LOTION [Soleil Toujours Perpetual Radiance Broad Spectrum SPF 20]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory perceptual training with fluoxetine (20 mg daily)
Study: 37414062
Drug: Sorafenib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib maintenance (400 mg orally twice daily)
Study: 32588334
Drug: Dietary magnesium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary magnesium supplementation (2, 4, or 6 g/kg MgO)
Study: 35672956
Drug: Sustained specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained specialist treatment (ST)
Study: 35672956
Drug: Sustained specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained specialist treatment including Parent groups (ST + P)
Study: 36482530
Drug: TLE 400
Normalized name: Stinging Nettle 400 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLE 400 (efavirenz 400 mg)
Study: 36482530
Drug: TLE 600
Normalized name: PLEURAL DRAINAGE BOTTLE 600ML BRAUN #622272
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLE 600 (efavirenz 600 mg)
Study: 32664948
Drug: Extended 6-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended 6-day course of artemether-lumefantrine and additional single low-dose primaquine (0.25 mg/kg) administered with the last dose.
Study: 35658345
Drug: PKU‐ML model
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKU‐ML model (machine learning diagnostic model)
Study: 35725295
Drug: IST discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IST discontinuation
Study: 34347359
Drug: Prior metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior metformin use
Study: 34347359
Drug: Long-term metformin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term metformin use
Study: 32445077
Drug: Ketorolac (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (60 mg with 2% lignocaine)
Study: 32445077
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg with 2% lignocaine)
Study: 35256446
Drug: Acetazolamide 750
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 750 mg/day
Study: 33594439
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 100% oxygen at 2.0 atmospheres per session, 5 days per week, for 8 weeks.
Study: 33594439
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment arm (control group) receiving HBOT after a 12-week waiting period.
Study: 32650814
Drug: OHI, 6-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI, 6-month use of powered tooth brushing, and 0.2% chlorhexidine gluconate mouth rinse (10 ml twice daily)
Study: 34362422
Drug: Increasing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing treatment effect on the intermediate variable
Study: 34362422
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of an interaction between treatment and confounder
Study: 35061894
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg once daily)
Study: 33974725
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder supplementation (1,600 mg/d for 3 months)
Study: 33687748
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/mL (IDeg‐100)
Study: 32529467
Drug: Gossypol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gossypol (20 mg once daily on days 1 to 14 every 21 days) combined with docetaxel (75 mg/m2) and cisplatin (75 mg/m2)
Study: 32529467
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with docetaxel (75 mg/m2) and cisplatin (75 mg/m2)
Study: 33080655
Drug: No anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anesthesia or pain medication
Study: 33080655
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (sedation, local anesthesia, nonsteroidal antiinflammatory drugs)
Study: 33736863
Drug: Denture cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture cleaning tablets
Study: 33736863
Drug: Denture cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture cleaning tablets plus gingival cleaning tablets
Study: 35144837
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) 1 g IV
Study: 36099069
Drug: Saxagliptin +
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin + Metformin (Saxa + Met)
Study: 32716358
Drug: Polypharmacy (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (defined as taking five or more medications regularly)
Study: 36708956
Drug: Vortioxetine 10-20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10-20 mg/day
Study: 34752723
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) gel pulpotomy
Study: 34098993
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice supplementation (200 ml per day for 7 weeks)
Study: 33263744
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus 100 mg of aspirin once per day
Study: 33263744
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin once per day
Study: 33298013
Drug: Guideline concordant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline concordant Standard Care (gcSC) with adjunct exercise treatment for 12 weeks
Study: 33298013
Drug: Adjunct exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct exercise treatment
Study: 36011639
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment provided in Seremban health clinics
Study: 35276716
Drug: Lurasidone 40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40-80 mg/d
Study: 35276716
Drug: Lurasidone 120-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 120-160 mg/d
Study: 35961517
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of autologous skeletal muscle–derived cells
Study: 35961517
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of autologous skeletal muscle–derived cells
Study: 32447858
Drug: Nerve trunk
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve trunk stimulation therapy (Chize, Neiguan, Xiaohai)
Study: 32440111
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice daily (BID)
Study: 34528132
Drug: 75 mL
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mL water (HYP)
Study: 33892653
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg/kg intravenous bolus 10 hours before surgery)
Study: 34939580
Drug: Pentavac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac vaccine
Study: 34939580
Drug: Shan 5
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shan 5 vaccine
Study: 34939580
Drug: Pentabio vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentabio vaccine
Study: 33626198
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy & Exercises Group (MTEG)
Study: 34563973
Drug: Oral Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ketamine
Study: 36004709
Drug: HD +
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD + P. ostreatus (1 kg of P. ostreatus per week, four portions of 250 g)
Study: 33945982
Drug: Thiamine 200
Normalized name: thiamine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 200 mg IV three times daily for 7 days
Study: 35016629
Drug: Conventional Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Occupational Therapy (COT)
Study: 36371623
Drug: Technology-based Comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-based Comprehensive Cardiac Rehabilitation Therapy (TaCT) electronic cardiac rehabilitation (eCR) intervention
Study: 36324127
Drug: Twice-daily test
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily test mouth rinse containing Cetylpyridinium chloride (CPC) and essential oils for 12 weeks
Study: 36123102
Drug: Highly absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly absorbable oral curcumin (brand name: curcuRouge)
Study: 38638400
Drug: Ranibizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.1 mg
Study: 33176727
Drug: Female treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female treatment and concurrent male partner treatment (7 days of combined antibiotics - oral metronidazole 400 mg BID and 2% clindamycin cream applied topically to the glans penis and upper shaft BID)
Study: 33176727
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care (female treatment only)
Study: 34154319
Drug: Aminoglycosides/colistin/combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides/colistin/combination
Study: 32087836
Drug: MI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-based treatment engagement intervention (TE)
Study: 34583841
Drug: Solution-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused therapy (SFT)
Study: 34371978
Drug: All preload
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All preload treatments (IC and HC)
Study: 32333168
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (BWLT) - 10,000 lx, active arm, twice-daily 1-hour sessions for 4 weeks
Study: 32333168
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light therapy (DRLT) - < 300 lx, control arm, twice-daily 1-hour sessions for 4 weeks
Study: 33893842
Drug: Light-emitting diode
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-emitting diode therapy (LEDT)
Study: 32574773
Drug: AKB-9778 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AKB-9778 treatment
Study: 37061370
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (0.5 mL) HPV vaccine
Study: 37061370
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1.0 mL) HPV vaccine